The FDA has approved the Optune Pax wearable device for the treatment of locally advanced pancreatic cancer through TTFields (Tumor Treating Fields) technology, which delivers alternating electric fields.[1] It is the first device of its kind approved for this disease in nearly 30 years.[1] The device is intended for the treatment of tumors in patients with locally advanced pancreatic cancer.[1] The Optune Pax is a wearable device that the patient wears on their body.[1] TTFields stop the growth of cancer cells by acting differently than chemotherapy or radiation.[2][3] In similar indications, such as glioblastoma, the Optune device in combination with temozolomide significantly prolongs survival; the number of two-year survivors was 50% higher compared to chemotherapy alone.[1] The approval is based on the FDA's priority review for life-threatening conditions with clinical benefits.[1]